AstraZeneca: AstraZeneca's AZD0780, a novel oral PCSK9 inhibitor, demonstrates significant LDL cholesterol reduction in PURSUIT phase IIb trial

Positive results from the PURSUIT phase IIb trial for AstraZeneca's AZD0780 demonstrated a statistically significant low─density lipoprotein cholesterol (LDL─C) reduction when administered on top of standard─of─care